Pharmather Hldgs Ltd PHRRF

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia, procedural sedation as well as depression, surgical and pain management. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX wearable pump for the maintenance of general anesthesia for diagnostic, surgical procedures and pain indications. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. The company also develops Personaliz3D Peptides, focused on developing and commercializing personalized peptide products and protocols using 3D printing and artificial intelligence technologies. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; with the University of Arizona for the development and commercialization of ketamine in the treatment of Parkinson's disease; as well as holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology. The company was incorporated in 2019 and is headquartered in Toronto, Canada.